NeoStem Blog

Seizing an Opportunity to Fight Cancer

Strategic acquisitions have been the cornerstone of NeoStem’s growth and have been selected in order to p.... More

Insider Buying

On July 1st, approximately 14,456 shares of the Company’s common stock were purchased by employees of th.... More

Meet Dr. Douglas Losordo, Chief Medical Officer

We are pleased to introduce Dr. Douglas Losordo, Chief Medical Officer of NeoStem, Inc.  Dr. Losordo is a well-known cardiologist and an expert in stem... More

Dr. Robin Smith on Completion of PreSERVE Phase 2 Enrollment

This month I had the pleasure of announcing that NeoStem has completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blind placebo-controlled... More

CEO Comments on the Closing of NeoStem’s Public Offering

We believe the financing environment for emerging biopharmaceutical companies such as NeoStem has been very favorable – the general interest among investors is stronger than... More

A Letter to Shareholders from Dr. Robin Smith

August 30, 2013 Dear NeoStem Shareholders, NeoStem, a leader in the emerging cellular therapy market, continues to position itself for success through scientific discovery; a... More

US National Bioeconomy Report Validates NeoStem’s Cell Therapy Approach

The April 2012 US National Bioeconomy Blueprint released by the White House focuses on five key objectives which relate to health, manufacturing, energy, environment, education and agriculture.... More

NeoStem CEO’s Letter to Shareholders

Dear NeoStem Shareholders, NeoStem (NYSE MKT:NBS) is rapidly emerging as a technology and market leading company in the fast developing cell therapy market. Our multifaceted... More

My Letter to NeoStem’s Shareholders: A Look Back at 2011 and Looking Forward

Earlier today I sent the following letter to our shareholders. Dear NeoStem Shareholders, We would like to take a moment to both look back at... More

Building NeoStem’s Leadership in the Pharmaceutical Industry

As we continue to take on a leadership role in the development of cell therapies, the commercialization of our products, whether alone or in partnership... More

The Advantages of AMR-001, NeoStem’s Cardiovascular Cell Therapy

We here at NeoStem are extremely excited about our acquisition of Amorcyte, Inc., a cardiovascular cell therapy company originally founded by our subsidiary, Progenitor Cell... More

The Vatican Adult Stem Cell Conference

I want to take this opportunity to share excerpts from comments I made on November 9 at the NeoStem co-sponsored Vatican Adult Stem Cell Conference... More